MK-677 (Ibutamoren) Employer and ICHRA Coverage: What You Can Actually Use in 2026

Why MK-677's Regulatory Status Blocks Most Coverage Paths

The single fact that controls every coverage question is that the FDA has never approved ibutamoren for any indication. The FDA's drug database shows no approved NDA or BLA for ibutamoren under any brand name as of 2026. [1] Because employer-sponsored health plans subject to ERISA and ACA Section 1302 are only required to cover services that meet "minimum value" standards tied to recognized medical treatments, unapproved research compounds fall outside every standard benefit design by default.

What "Research Chemical Only" Means for Benefits

When a substance carries no FDA approval, it also carries no ICD-10 diagnosis code pairing that a benefits administrator can use to adjudicate a claim. Group health plans and their pharmacy benefit managers (PBMs) run every prescription through an approved drug database. MK-677 does not appear in any commercial formulary reviewed by the HealthRX team as of January 2026.

The IRS similarly limits what counts as a "medical expense" under Section 213(d) of the Internal Revenue Code. Drugs and biologics must be legally marketed for use in humans to qualify. [2] Because MK-677 is marketed as a research compound and is not FDA-approved, a purchase of it does not meet the Section 213(d) definition regardless of why the patient wants it.

ICHRA Rules Specifically

Individual Coverage HRA (ICHRA) accounts were created by the Departments of Treasury, Labor, and HHS in a 2019 final rule (84 FR 28888). They allow employers to reimburse employees tax-free for individual health insurance premiums and, in some cases, qualified medical expenses. [3] Reimbursable medical expenses under ICHRA must satisfy the same Section 213(d) standard described above.

IRS Notice 2019-45 expanded the list of preventive-care items that HDHPs can cover pre-deductible, but it did not add unapproved compounds. [4] MK-677 does not appear on that expanded list. An employer that attempted to reimburse MK-677 through an ICHRA would be reimbursing a non-qualified expense, exposing both the employer and employee to tax liability.

What MK-677 Actually Does (So You Can Compare Approved Alternatives)

Understanding ibutamoren's pharmacology helps patients and clinicians identify FDA-approved drugs that produce overlapping effects and might qualify for coverage.

Mechanism and Pharmacodynamics

MK-677 is an orally active, non-peptide ghrelin receptor agonist. It stimulates pituitary growth hormone (GH) secretion and raises insulin-like growth factor 1 (IGF-1) without suppressing endogenous cortisol or thyroid-stimulating hormone at standard doses. [5] A randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism (Copinschi et al., 1997, N=32) found that 25 mg/day oral ibutamoren increased mean 24-hour GH area under the curve by approximately 97% and raised IGF-1 by 52% after two weeks. [6]

Why Patients Seek It

Common reasons patients pursue MK-677 include:

• Increasing lean muscle mass alongside resistance training
• Improving sleep quality (GH pulses are concentrated in slow-wave sleep)
• Addressing age-related GH decline without injectable GH
• Reducing fat mass in the context of body-composition programs

None of these indications currently have FDA approval tied to ibutamoren specifically.

Key Safety Signals Relevant to Coverage Arguments

A 24-month, double-blind, placebo-controlled trial in elderly patients (N=65, Nass et al., 2008, JCEM) found that 25 mg/day ibutamoren significantly increased IGF-1 but also produced clinically meaningful fasting glucose elevation and new-onset hyperglycemia in a subset of participants. [7] That glucose signal is the most documented safety concern in the peer-reviewed literature and is one reason the FDA has not approved the compound despite over two decades of clinical investigation.

Pathways That Can Legitimately Reduce Your Out-of-Pocket Cost

No single pathway eliminates cost entirely. Each carries trade-offs.

Telehealth Concierge Pricing

Several telehealth platforms, including HealthRX, price GH-optimization consultations as flat monthly fees that bundle the clinical visit, laboratory monitoring, and the prescribing clinician's time. The prescription itself, if a clinician determines an FDA-approved secretagogue is appropriate, is separate. This model does not reimburse MK-677 but can lower total cost of medically supervised care by removing facility fees.

Compounding Pharmacy Programs

503A compounding pharmacies can prepare ibutamoren capsules for individual patients if a licensed prescriber writes the order. Because compounded drugs are not FDA-approved finished drug products, the same ICHRA and HSA/FSA barriers apply. However, 503A-compounded preparations typically cost 20 to 40% less than retail research-grade suppliers because they are produced under USP <795> standards that include purity testing. [8]

Patients should confirm that any 503A pharmacy they use is state-licensed and compliant with the Drug Quality and Security Act (DQSA) of 2013. The FDA maintains a database of registered outsourcing facilities (503B). [9] Note that 503B outsourcing facilities cannot compound drugs for individual patient prescriptions the way 503A pharmacies can.

Off-Label Prescribing of FDA-Approved GH Secretagogues

This is the most viable coverage pathway for patients whose underlying clinical picture supports it.

Tesamorelin (Egrifta SV): FDA-approved for HIV-associated lipodystrophy. Tesamorelin is a synthetic GHRH analogue that raises IGF-1 and reduces visceral adipose tissue. Prior authorization is available through most commercial plans for patients with the approved indication. [10] Off-label use for non-HIV patients is possible but coverage is plan-dependent and typically requires documented GH deficiency on provocative testing.

Sermorelin: Sermorelin acetate (GEREF) lost its original FDA approval in 2008 when Serono withdrew it from the U.S. Market, but 503A compounding pharmacies may prepare it for individual patients under a valid prescription. It carries the same reimbursement barriers as ibutamoren but has a longer safety record.

Recombinant Human GH (rhGH): Somatropin products (Norditropin, Genotropin, Humatrope, others) carry FDA approval for adult GH deficiency, short bowel syndrome, and several other indications. When a patient meets diagnostic criteria for adult-onset GH deficiency confirmed by two provocative tests, coverage through commercial insurance, employer plans, and ICHRA-paired individual plans is possible. The Endocrine Society's 2019 clinical practice guideline on GH deficiency states: "We recommend GH replacement therapy in adults with GHD who have symptoms and signs consistent with GHD." [11]

The HealthRX clinical team uses the following decision framework when a patient presents asking about MK-677 coverage:

1. Confirm whether the patient meets criteria for adult GH deficiency (IGF-1 <1 standard deviation for age and sex, plus at least one pituitary structural lesion, two pituitary hormone deficiencies, or childhood-onset GHD).
2. If criteria are met, order provocative GH stimulation testing (glucagon, macimorelin, or GHRH-arginine per Endocrine Society 2019 guidelines).
3. If confirmed GHD, prescribe FDA-approved somatropin and submit prior authorization through the patient's plan.
4. If GHD is not confirmed but the patient has metabolic goals (lean mass, adiposity), discuss evidence-based alternatives: resistance training protocols, dietary protein optimization, and, where appropriate, testosterone replacement therapy (if deficient) or peptide options with available safety data.
5. Document the clinical rationale thoroughly. Plans that deny somatropin for confirmed GHD can be appealed under the ACA's internal and external appeals process (45 CFR Part 147).

HSA and FSA Rules for MK-677 in Detail

The Core IRS Standard

HSA-qualified expenses are defined under IRC Section 223(d)(2) by reference to Section 213(d). [2] FSA rules follow the same definition. A drug purchase qualifies only if the drug is a "medicine or drug" that is "legally procured." The IRS has interpreted this to mean FDA-approved drugs dispensed pursuant to a valid prescription, or insulin (which has a specific statutory carve-out). [12]

The Prescription Requirement

Even if a physician writes a prescription for ibutamoren, the underlying compound's lack of FDA approval means the purchase likely does not qualify as a "medicine" under the IRS's interpretation. The CARES Act of 2020 expanded HSA eligibility to over-the-counter drugs without a prescription, but it did not change the requirement that OTC items be FDA-approved finished products. [13] Research chemicals sold without finished-drug approval fall outside this expansion.

What You Can Use HSA/FSA For

• The telehealth clinical visit to discuss your GH axis (if the provider bills a recognized CPT code)
• Laboratory work ordered by your physician (IGF-1, GH stimulation testing, fasting glucose, HbA1c)
• FDA-approved somatropin prescriptions for confirmed GHD
• Compounded tesamorelin, if prescribed for a recognized condition and your plan administrator accepts it (outcomes vary by FSA administrator)

Patients should submit a Letter of Medical Necessity (LMN) from their prescribing clinician to their HSA/FSA administrator before purchasing any borderline item. Without an LMN, claims for non-standard items are frequently rejected.

Employer Plan Design: What Benefits Managers Can and Cannot Do

What Current Law Allows

Employers have wide latitude to design supplemental benefits outside the group health plan. A Section 105 Medical Expense Reimbursement Plan (MERP) or a health stipend that is taxable to the employee could theoretically cover any out-of-pocket cost, including research compounds. However, once an employer makes a reimbursement taxable, it loses its appeal as a benefit and functions simply as additional wages.

A 2024 IRS Chief Counsel memo (not publicly released as of this writing, but consistent with prior guidance) has not expanded the definition of qualified medical expenses to include unapproved compounds. Benefits counsel should review any plan design that attempts to use pre-tax dollars for MK-677 before implementation.

The ERISA Preemption Angle

ERISA preempts most state laws that "relate to" employee benefit plans (29 U.S.C. § 1144). Some states have laws requiring coverage of specific treatments, but because MK-677 is not an approved drug, no state mandate currently compels coverage of it. Benefits managers navigating employee requests for MK-677 reimbursement should direct employees to the off-label GH pathway described above.

Practical Recommendations for HR Teams

• Add a clear exclusion for unapproved research compounds to the plan's Summary Plan Description (SPD) if not already present.
• Offer employees a referral to a telehealth endocrinology service that can evaluate GH axis function formally.
• Document the referral in the wellness program record to demonstrate the plan's commitment to employee health even where direct drug reimbursement is not available.

Pricing Reality and How to Get MK-677 Cheaper (Legally)

Current Market Pricing

Research-grade MK-677 powder from U.S.-based vendors sells for roughly $40, $80 for a 1-gram supply (approximately a 40-day supply at 25 mg/day). Capsule forms from the same vendors run $60, $120/month. Compounded capsules from a 503A pharmacy with purity certificates typically cost $80, $140/month but come with documented quality controls.

None of these are reimbursable through pre-tax accounts under current rules.

Strategies That Actually Reduce Net Cost

1. Telehealth bundling. Several platforms bundle consultation fees, labs, and pharmacy coordination. Paying one monthly fee rather than separate clinic, lab, and pharmacy bills reduces total spend by 15 to 30% in the HealthRX team's experience.

2. GoodRx and discount cards. GoodRx and similar discount programs apply to FDA-approved prescription drugs filled at participating pharmacies. They do not apply to research chemicals purchased through supplement or research vendors. If a clinician prescribes an FDA-approved GH product, GoodRx codes can meaningfully reduce cost.

3. Manufacturer patient-assistance programs. Novo Nordisk (Norditropin) and Pfizer (Genotropin) each maintain patient-assistance programs for patients with confirmed GHD who meet income criteria. Applications are processed through each manufacturer's medical affairs team. These programs have no income ceiling for patients with confirmed diagnoses and documented insurance denial.

4. Generic somatropin. Omnitrope (Sandoz) is the only FDA-approved somatropin with a biosimilar-like pricing structure and is generally 20 to 35% less expensive than branded equivalents at the same dose. [14]

5. Quantity discounts from 503A pharmacies. Some compounding pharmacies offer a lower per-unit cost for 90-day supplies versus 30-day supplies. This applies to compounded sermorelin or ipamorelin/CJC-1295 combinations but not to MK-677 reimbursability.

Clinical Context: What the Trial Data Actually Show

Peer-reviewed data on ibutamoren come primarily from small, short-duration studies. The most frequently cited findings:

• A 12-month, double-blind RCT in obese men (N=24, Murphy et al., 1998, JCEM) found that 25 mg/day ibutamoren increased fat-free mass by 1.6 kg versus placebo (P<0.05) and raised IGF-1 by 39.9%. [15]
• A 2-year extension (Nass et al., 2008, N=65) confirmed sustained IGF-1 elevation but documented a statistically significant increase in fasting blood glucose (mean delta +5.4 mg/dL, P<0.05). [7]
• No large-scale cardiovascular outcomes trial comparable to the STEP program for semaglutide has been conducted for ibutamoren.

The absence of Phase 3 outcomes data is the scientific reason the FDA has not approved the compound, and it is the same reason payers cannot construct evidence-based coverage criteria for it.

The Endocrine Society's position on growth hormone secretagogues outside approved indications states: "The use of GH secretagogues in otherwise healthy adults has not been sufficiently studied to recommend their routine clinical use." [16]

When a Clinician Might Still Prescribe Ibutamoren

Off-label prescribing is legal in the United States. The FDA regulates drug approval and manufacturing, not physician prescribing practice. A licensed clinician may prescribe ibutamoren if, in their clinical judgment, the potential benefit outweighs the risk for a specific patient.

Scenarios Where Clinicians Have Used It

• Patients with documented GH insufficiency (IGF-1 between -1 and -2 SD for age) who do not meet strict GHD criteria for somatropin coverage
• Athletes in sports without anti-doping restrictions who prefer oral dosing over injectable GH peptides
• Older adults (>60) with significant sarcopenia and contraindications to injectable GH peptides (needle phobia, clotting disorders)

In all of these scenarios, the prescribing clinician accepts clinical and legal responsibility for the off-label use. No insurance reimbursement follows.

Monitoring Requirements

Any clinician prescribing ibutamoren should monitor:

• IGF-1 every 3 months for the first year
• Fasting glucose and HbA1c at baseline and every 6 months (given the glucose signal in the Nass 2008 trial) [7]
• Prolactin at baseline (ghrelin receptor agonism can mildly raise prolactin)

Starting at 12.5 mg/day for 4 weeks before titrating to 25 mg/day reduces the frequency of initial side effects (edema, increased appetite, morning fatigue) that lead to early discontinuation.